Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NEO212 + FOLFIRI + bevacizumab
- Development stage
- Unknown
- Lead developer
- NEONC Technologies
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
NEO212 + FOLFIRI + bevacizumab is a combination cancer therapy consisting of the investigational agent NEO212, the standard chemotherapy regimen FOLFIRI, and bevacizumab. FOLFIRI includes folinic acid (leucovorin), fluorouracil (5-FU), and irinotecan (Camptosar), which work together to halt tumor growth by interfering with DNA synthesis, RNA metabolism, and topoisomerase I activity, leading to cell death of rapidly dividing cells. Bevacizumab is a humanized monoclonal antibody that binds vascular endothelial growth factor A (VEGF-A), inhibiting angiogenesis (formation of new blood vessels) critical for tumor growth. Bevacizumab is FDA-approved for several cancers, including metastatic colorectal cancer, when combined with fluorouracil-based chemotherapy[1][2][6]. NEO212 is a conjugate molecule that has demonstrated experimental antitumor activity but is not approved for any indications; its mechanism includes DNA alkylation and possibly other cytotoxic effects.
- Other names
- leucovorincalcium folinateFA5FUCamptosar
02
Targets
Beyond the preview
Go deeper on NEO212 + FOLFIRI + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NEO212 + FOLFIRI + bevacizumab.